Peter L. Anderson
Peter L. Anderson
University of Colorado
Verified email at - Homepage
Cited by
Cited by
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
RM Grant, JR Lama, PL Anderson, V McMahan, AY Liu, L Vargas, ...
New England Journal of Medicine 363 (27), 2587-2599, 2010
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
RM Grant, PL Anderson, V McMahan, A Liu, KR Amico, M Mehrotra, ...
The Lancet infectious diseases 14 (9), 820-829, 2014
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men
PL Anderson, DV Glidden, A Liu, S Buchbinder, JR Lama, JV Guanira, ...
Science translational medicine 4 (151), 151ra125-151ra125, 2012
Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services
AY Liu, SE Cohen, E Vittinghoff, PL Anderson, S Doblecki-Lewis, O Bacon, ...
JAMA internal medicine 176 (1), 75-84, 2016
Cabotegravir for HIV prevention in cisgender men and transgender women
RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ...
New England Journal of Medicine 385 (7), 595-608, 2021
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III …
E Abraham, PF Laterre, J Garbino, S Pingleton, T Butler, T Dugernier, ...
Critical care medicine 29 (3), 503-510, 2001
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised …
KH Mayer, JM Molina, MA Thompson, PL Anderson, KC Mounzer, ...
The Lancet 396 (10246), 239-254, 2020
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure
JR Castillo-Mancilla, JH Zheng, JE Rower, A Meditz, EM Gardner, ...
AIDS research and human retroviruses 29 (2), 384-390, 2013
An HIV preexposure prophylaxis demonstration project and safety study for young MSM
SG Hosek, B Rudy, R Landovitz, B Kapogiannis, G Siberry, B Rutledge, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 74 (1), 21-29, 2017
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm
JE Haberer, DR Bangsberg, JM Baeten, K Curran, F Koechlin, KR Amico, ...
Aids 29 (11), 1277-1285, 2015
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
S Delany-Moretlwe, JP Hughes, P Bock, SG Ouma, P Hunidzarira, ...
The Lancet 399 (10337), 1779-1789, 2022
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV‐infected patients
JJ Kiser, ML Carten, CL Aquilante, PL Anderson, P Wolfe, TM King, ...
Clinical Pharmacology & Therapeutics 83 (2), 265-272, 2008
Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy
PL Anderson, AY Liu, JR Castillo-Mancilla, EM Gardner, SM Seifert, ...
Antimicrobial agents and chemotherapy 62 (1), 10.1128/aac. 01710-17, 2018
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
PL Anderson, JJ Kiser, EM Gardner, JE Rower, A Meditz, RM Grant
Journal of antimicrobial chemotherapy 66 (2), 240-250, 2011
Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States
SG Hosek, RJ Landovitz, B Kapogiannis, GK Siberry, B Rudy, B Rutledge, ...
JAMA pediatrics 171 (11), 1063-1071, 2017
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance
EM Gardner, WJ Burman, JF Steiner, PL Anderson, DR Bangsberg
Aids 23 (9), 1035-1046, 2009
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients
JJ Kiser, CL Aquilante, PL Anderson, TM King, ML Carten, CV Fletcher
JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (3), 298-303, 2008
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study
PL Anderson, J Lamba, CL Aquilante, E Schuetz, CV Fletcher
JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (4), 441-449, 2006
The cellular pharmacology of nucleoside-and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities
PL Anderson, TN Kakuda, KA Lichtenstein
Clinical Infectious Diseases 38 (5), 743-753, 2004
Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial
K Mulligan, DV Glidden, PL Anderson, A Liu, V McMahan, P Gonzales, ...
Clinical infectious diseases 61 (4), 572-580, 2015
The system can't perform the operation now. Try again later.
Articles 1–20